Evommune, Inc.
EVMNNYSE
$12.14
↑ +3.7%Jul 17 close · end-of-day
Price
1Y↓ -40.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$74.5M
Enterprise Value
-$137.0M
P/E
—
P/S
5.7
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
-102.9%
Dividend Yield
—
Revenue (TTM)
$13.0M
Net Income (TTM)
-$68.9M
Free Cash Flow (TTM)
-$76.7M
Gross Margin
—
Operating Margin
-623.6%
Net Margin
—
ROE
—
ROIC
-68.8%
Debt / Equity
—
Net Cash
$211.5M
Return 1Y
—
Company profile
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. Our principal executive offices are located in Palo Alto, CA.
- CEO
- Luis Peña
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 45
- Headquarters
- California
- Website
- www.evommune.com
Management & directors
- Carver KyleChief Financial Officer
- Drew Janice SuzannChief of Dev. Operations
- Patel Jeegar PravinkumarChief Scientific Officer
- Pena Luis C.President & CEO
- Moss Gregory S.Chief Business & Legal Officer
- Bauer EugeneChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
EVMN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.64↓ -93.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | $7.0M | $13.0M |
| Gross profit | — | — |
| Operating income | -$70.0M | -$81.1M |
| Net income | -$66.8M | -$68.9M |
| Diluted EPS | -$45.29 | -$11.22 |
| Operating cash flow | -$58.2M | -$76.4M |
| Free cash flow | -$58.3M | -$76.7M |
| Gross margin | — | — |
| Operating margin | -1000.2% | -623.6% |
| Net margin | -954.4% | -529.8% |
| Line item | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Revenue | — | $3.0M | $10.0M | $0.00 |
| Gross profit | — | — | — | — |
| Operating income | -$16.5M | -$15.0M | -$13.3M | -$24.0M |
| Net income | -$15.9M | -$14.6M | -$12.5M | -$21.7M |
| Diluted EPS | -$10.47 | -$9.48 | -$8.07 | -$0.64 |
| Operating cash flow | — | -$23.9M | — | -$27.5M |
| Free cash flow | — | -$23.9M | — | -$27.6M |
| Gross margin | — | — | — | — |
| Operating margin | — | -501.1% | -133.3% | — |
| Net margin | — | -485.2% | -124.8% | — |
Company news
Jun 30, 2026
Jun 29, 2026
- 21d agoEvommune terminates oral drug’s development in CSUclinicaltrialsarena.com
- 21d agoEvommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)investorshub.advfn.com
- 21d agoEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticariafinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Carver Kyle· Chief Financial Officer | Buy | 1,000 | $13.26 | $13,260.00 | filing |
| 2026-07-07 | Kirsch Arthur S | Buy | 10,000 | $13.30 | $133,000.00 | filing |
| 2026-06-22 | Drew Janice Suzann· Chief of Dev. Operations | Sale | 20,000 | $22.63 | $452,600.00 | filing |
| 2026-06-22 | Pena Luis C.· President & CEO | Sale | 7,438 | $22.71 | $168,916.98 | filing |
| 2026-06-22 | Drew Janice Suzann· Chief of Dev. Operations | Option exercise | 16,161 | $2.99 | $48,321.39 | filing |
| 2026-06-22 | Patel Jeegar Pravinkumar· Chief Scientific Officer | Sale | 1,488 | $22.50 | $33,480.00 | filing |
| 2026-06-22 | Drew Janice Suzann· Chief of Dev. Operations | Option exercise | 3,839 | $3.84 | $14,741.76 | filing |
| 2026-06-22 | Patel Jeegar Pravinkumar· Chief Scientific Officer | Option exercise | 1,488 | $3.84 | $5,713.92 | filing |
| 2026-06-02 | Cohen David E | Sale | 5,456 | $20.21 | $110,265.76 | filing |
| 2026-06-02 | Cohen David E | Sale | 600 | $21.38 | $12,828.00 | filing |
| 2026-06-01 | Pena Luis C.· President & CEO | Sale | 16,787 | $22.74 | $381,736.38 | filing |
| 2026-06-01 | Patel Jeegar Pravinkumar· Chief Scientific Officer | Sale | 16,687 | $22.74 | $379,462.38 | filing |
| 2026-06-01 | Patel Jeegar Pravinkumar· Chief Scientific Officer | Option exercise | 13,512 | $3.84 | $51,886.08 | filing |
| 2026-05-28 | Carver Kyle· Chief Financial Officer | Sale | 18,175 | $22.84 | $415,117.00 | filing |
| 2026-05-28 | Moss Gregory S.· Chief Business & Legal Officer | Sale | 14,223 | $22.83 | $324,711.09 | filing |
| 2026-05-28 | Carver Kyle· Chief Financial Officer | Option exercise | 15,000 | $2.99 | $44,850.00 | filing |
| 2026-05-28 | Moss Gregory S.· Chief Business & Legal Officer | Option exercise | 14,223 | $1.71 | $24,321.33 | filing |
| 2026-02-17 | LSP 7 Cooperative UA | Award | 358,680 | $27.88 | $10.0M | filing |
| 2026-02-17 | Verduyn-van Weegen Felice Isabel | Award | 358,680 | $27.88 | $10.0M | filing |
| 2026-02-17 | RA CAPITAL MANAGEMENT, LLC | Award | 35,868 | $27.88 | $999,999.84 | filing |
| 2025-12-19 | Hopfner Robert Lorne | Buy | 1,000 | $17.35 | $17,350.00 | filing |
| 2025-12-09 | Pena Luis C.· President & CEO | Tax withholding | 28,138 | $17.84 | $501,981.92 | filing |
| 2025-12-09 | Moss Gregory S.· Chief Business & Legal Officer | Tax withholding | 13,624 | $17.84 | $243,052.16 | filing |
| 2025-12-09 | Carver Kyle· Chief Financial Officer | Tax withholding | 13,290 | $17.84 | $237,093.60 | filing |
| 2025-12-09 | Patel Jeegar Pravinkumar· Chief Scientific Officer | Tax withholding | 7,513 | $17.84 | $134,031.92 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.